Summary
Nine previously untreated patients with Philadelphia chromosome-positive chronic myelocytic leukemia (CML) were treated with recombinant interferon alpha 2a (rIFN-alpha 2a) and hydroxyurea. Patients received 6×106 U rIFN-alpha 2a daily for the first week and 3×106 U rIFN-alpha 2a daily for the second week. As maintenance treatment starting on day 15, patients received 3×106 U rIFN-alpha 2 a 3 times a week. Simultaneously, hydroxyurea was given, starting at a dose of 40 mg/kg on day one. The maintenance dosage was adjusted to the white blood cell count. Two patients responded with complete hematological remissions but without cytogenetic and molecular-genetic improvements. Seven patients responded with partial hematological remissions. Response to therapy was rapid; normal white blood cell counts were reached after a median of 12 days. The doses of rIFN-alpha 2a and hydroxyurea needed to keep the leucocyte count in the normal range were low (3×106 U rIFN-alpha 2a 3 times per week, 0.5–1.5 g hydroxyurea/day). Acute toxicity of the combination therapy consisted of fever (9 of 9 patients), flulike symptoms (7 of 9 patients), pruritus and/or rash (3 of 9 patients) and evidence of a tumor cell lysis syndrome (1 of 9 patients). The side effects were not dose-limiting. Combination therapy with rIFN-alpha 2a and hydroxyurea for CML is well tolerated and allows quick and effective hematological control of the disease.
Similar content being viewed by others
References
Alimena G, Morra E, Lazzarino M, Liberati AM, Montefusco E, Inverardi D, Bernasconi P, Mancini M, Donti E, Grignani F, Bernasconi C, Dianzani F, Mandelli F (1988) Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72: 642–647
Anger BR, Carbonell F, Braunger I, Heinze B, Gutensohn W, Thiel E, Heimpel H (1988) Blast crisis of Philadelphia chromosome-positive chronic myelocytic leukemia (CML). Blut 57: 131–137
Bolin RW, Robinson WA, Sutherland J, Hamman RF (1982) Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 50: 1683–1687
Hehlmann R, Anger BR, Messerer D, Zankovitch R, Bergmann L, Kolb HJ, Meyer P, Essers U, Queisser U, Vaupel H, Walter F, Hossfeld DK, Zimmermann R, Heiss F, Mende S, Tigges FJ, Kleeberg UR, Pralle H, Kayser W, Tichelli A, Faulhaber JD, Raeth U, Schubert H, Bross K, Schlag R, Schmidt L, Weissenfels I, Heinze B, Georgii A, Queisser W, Heimpel H (1988) Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Blut 56: 87–91
Kurzrock R, Talpaz M, Kantarijan H et al. (1987) Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood 70: 943–947
Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG (1986) Alpha-2-Interferon — erste Behandlungsergebnisse bei der chronisch myeloischen Leukämie. DMW 111: 765–767
Rushing D, Goldman JM, Gibbs G et al. (1982) Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia. Am J Clin Oncol 5: 307–313
Talpaz M, Kantarijan H, Kurzrock R, Gutterman JU (1988) Therapy of chronic myelogenous leukemia: chemotherapy and interferons. Semin Hematol 25: 62–73
Talpaz M, Kantarijan H, Kurzrock R, McCredie K, Keating MJ, Trujillo JM, Gutterman JU (1987) Clinical investigation of human leukocyte interferon in chronic myelogenous leukemia. Blood 69: 1280–1288
Talpaz M, Kantarijan H, McCredie K, Trujillo JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Anger, B., Porzsolt, F., Leichtle, R. et al. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 58, 275–278 (1989). https://doi.org/10.1007/BF00320165
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320165